Combining targeted drug with local treatments may extend control of EGFR lung cancer

NCT ID NCT03410043

First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 19 times

Summary

This study looks at whether adding surgery or radiation to the targeted therapy osimertinib can help people with advanced EGFR-mutant non-small cell lung cancer live longer without the disease getting worse. About 173 participants with stage IIIB or IV lung cancer will be randomly assigned to receive osimertinib alone or osimertinib plus local treatments. The goal is to see if the combination improves progression-free survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • UCSF Medical Center-Mount Zion

    San Francisco, California, 94115, United States

  • University of Colorado

    Denver, Colorado, 80217-3364, United States

Conditions

Explore the condition pages connected to this study.